Gardasil prevents genital lesions in men in pivotal trial
This article was originally published in Scrip
Executive Summary
Merck & Co's cervical cancer vaccine Gardasil has shown in a pivotal trial in men to be 90% effective at preventing external genital lesions (primarily genital warts) in Phase III data presented at the EUROGIN International Multidisciplinary Conference.